Compare CENX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | ADMA |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | 2004 | 2012 |
| Metric | CENX | ADMA |
|---|---|---|
| Price | $52.64 | $16.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $53.00 | $28.50 |
| AVG Volume (30 Days) | ★ 2.2M | 1.9M |
| Earning Date | 05-22-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 795.74 | 723.08 |
| EPS | 0.40 | 0.40 |
| Revenue | ★ $1,893,200,000.00 | $42,219,783.00 |
| Revenue This Year | $16.83 | $22.13 |
| Revenue Next Year | $9.29 | $24.12 |
| P/E Ratio | $130.59 | ★ $40.83 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $13.05 | $13.50 |
| 52 Week High | $55.59 | $25.67 |
| Indicator | CENX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 43.40 |
| Support Level | $48.36 | $15.72 |
| Resistance Level | $54.82 | $16.77 |
| Average True Range (ATR) | 3.78 | 0.64 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 96.44 | 28.43 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.